Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 15, 2021 02:00 ET | Source: BIOPHYTIS SA

Biophytis Announces Closing of ADS Offering on Nasdaq Capital Market

ADS Offering of $20.1 million in gross proceeds closed on February 12, 2021.Biophytis’s ADSs began trading on the Nasdaq Capital Market on February 10, 2021. PARIS and CAMBRIDGE, Mass., Feb. 15,...
February 15, 2021 02:00 ET | Source: BIOPHYTIS SA

Biophytis annonce le Règlement-Livraison de son Offre ADS

Montant total de l’offre de 20,1 millions de U.S. dollars dont le règlement-livraison a eu lieu le 12 février 2021.Les ADSs de Biophytis ont été admises aux négociations sur le Nasdaq Capital Market...
February 10, 2021 09:16 ET | Source: BIOPHYTIS SA

Biophytis Announces Trading Resumption of its Ordinary Shares and Share Warrants on Euronext Growth

PARIS and CAMBRIDGE, Mass., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Biophytis (Euronext Growth Paris: ALBPS) (“Biophytis” or the “Company”), a clinical-stage biotechnology company focused on the...
February 10, 2021 09:16 ET | Source: BIOPHYTIS SA

Biophytis annonce la reprise des négociations de ses actions ordinaires et de ses bons de souscription d’actions sur Euronext Growth

PARIS et CAMBRIDGE, Mass., 10 févr. 2021 (GLOBE NEWSWIRE) -- BIOPHYTIS SA (Euronext Growth Paris : ALBPS), société de biotechnologie au stade clinique, spécialisée dans le développement de...
February 10, 2021 04:40 ET | Source: BIOPHYTIS SA

Biophytis Announces Pricing of $20.1 Million U.S. Initial Public Offering of American Depositary Shares and Approval to List on Nasdaq Capital Market

PARIS and CAMBRIDGE, Mass., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Biophytis (Euronext Growth Paris: ALBPS) (“Biophytis” or the “Company”), a clinical-stage biotechnology company focused on the...
February 10, 2021 04:28 ET | Source: BIOPHYTIS SA

Biophytis Announces Temporary Trading Halt of its Ordinary Shares and Share Warrants on Euronext Growth

PARIS and CAMBRIDGE, Mass., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Biophytis (Euronext Growth Paris: ALBPS) (“Biophytis” or the “Company”), a clinical-stage biotechnology company focused on the...
February 10, 2021 02:00 ET | Source: BIOPHYTIS SA

Biophytis annonce la Fixation du Prix de son Offre ADS et l’Approbation de l’Admission aux Négociations sur le Nasdaq Capital Market

PARIS et CAMBRIDGE, Mass., 10 févr. 2021 (GLOBE NEWSWIRE) -- BIOPHYTIS SA (Euronext Growth Paris : ALBPS), (« Biophytis » ou la « Société »), société de biotechnologie au stade clinique,...
February 10, 2021 02:00 ET | Source: BIOPHYTIS SA

Biophytis Announces Pricing of $20.1 Million U.S. Initial Public Offering of American Depositary Shares and Approval to List on Nasdaq Capital Market

PARIS and CAMBRIDGE, Mass., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Biophytis (Euronext Growth Paris: ALBPS) (“Biophytis” or the “Company”), a clinical-stage biotechnology company focused on the...
February 10, 2021 02:00 ET | Source: BIOPHYTIS SA

Biophytis Announces Temporary Trading Halt of its Ordinary Shares and Share Warrants on Euronext Growth

PARIS and CAMBRIDGE, Mass., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Biophytis (Euronext Growth Paris: ALBPS) (“Biophytis” or the “Company”), a clinical-stage biotechnology company focused on the...
February 10, 2021 02:00 ET | Source: BIOPHYTIS SA

Biophytis annonce la suspension temporaire du cours de ses actions ordinaires et de ses bons de souscription d’actions sur Euronext Growth

PARIS et CAMBRIDGE, Mass., 10 févr. 2021 (GLOBE NEWSWIRE) -- BIOPHYTIS SA (Euronext Growth Paris : ALBPS), société de biotechnologie au stade clinique, spécialisée dans le développement de...